JPMorgan Maintains "Neutral" Rating on Johnson & Johnson (JNJ.US): Two New Anticancer Drugs Show Promising Data, but Valuation Premium Limits Upside Potential

Zhitong Finance APP notes that the European Society for Medical Oncology (ESMO) Annual Congress has just concluded. This is one of the most important academic conferences in the global oncology field, and the data announced at the meeting often directly affects the stock prices and pipeline expectations of related pharmaceutical companies. Johnson & Johnson (JNJ.US) has become one of the most closely watched names in the large-cap pharmaceutical sector. In a research report released on October 25, JPMorgan judged that the early data released by Johnson & Johnson in the two major indications of prostate cancer and head and neck cancer provide potential differentiated competitiveness for its innovative drug pipeline.